Fibroblast growth factor receptor 1-Transformed mammary epithelial cells are dependent on RSK activity for growth and survival

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2244-2251

  Xian, Wa ^a   Pappas, Leontios ^a   Pandya, Darshan ^a   Selfors, Laura M ^a   Derksen, Patrick W ^c   De Bruin, Michiel ^c   Gray, Nathanael S ^a   Jonkers, Jos ^c   Rosen, Jeffrey M ^b   Brugge, Joan S ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; S6 KINASE; SMALL INTERFERING RNA;

ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; CELL ANCHORAGE; CELL ASSAY; CELL DEATH; CELL GROWTH; CELL LINE; CELL POLARITY; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM CELL; GENE ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CARCINOMA; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; GENETICS; MAMMARY GLAND; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL CELLS; HUMANS; MAMMARY GLANDS, HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION;

EID: 65549095986     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3398     Document Type: Article

References (34)

1. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-56.
2. Althuis MIX Dozier JM, Anderson WF, Devesa SS, Brinton LA Global trends in breast cancer incidence and mortality 1973-1997. Int J Epidemiol 2005;34:405-12.
3. Smith DB, Howell A, Wagstaff J. Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol 1987;23:979-82.
4. Mathieu MC, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004; 40:342-51.
5. Jirstrom K, Ryden L, Anagnostaki L, et al. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 2005;58:1135-42.
6. Reis-Filho JS, Simpson PT, Turner NC, et al. EGER1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 2006;12:6652-62.
7. Welm BE, Freeman KW, Chen M, Contreras A, Spencer DM, Rosen JM. Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland. J Cell Biol 2002; 157:703-14.
8. Xian W, Schwertfeger KL, Vargo-Gogola T, Rosen JM. Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Riol 2005;171:663-73.
9. Kang S, Dong S, Gu TL, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ ERK pathway. Cancer Cell 2007;12:201-14.
10. Shimamura A, Ballif RA, Richards SA, Blenis J. Rskl mediates a MEK-MAP kinase cell survival signal. Curr Riol 2000;10:127-35.
11. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SMS Lannigan DA. Identification of the first specific inhibitor of p90 rihosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 2005;65:1027-34.
12. Davies M, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother 2006;7:2243-61.
13. jonkers J, Berns A. Oncogene addiction: sometimes a temporary' slavery'. Cancer Cell 2004;6:535-8.
14. Sharma SV, Fischhach MA, Haber DA, Settleman j, "Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res 2006;12:4392-5s.
15. Debnath j, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003;30:256-68.
16. Nomura S, Yoshitomi H, Takano S, et al. FGF10/ FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br J Cancer 2008;99:305-13.
17. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbBl, reinitiates proliferation and induces luminal repopulation in epithelial acini. Mat Cell Biol 2001;3:785-92.
18. Zhao H, Langerod A, ji Y, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004;15:2523-36.
19. Cohen MS, Zhang C, Shokat KM, Taunton j. Structural bio informatics-based design of selective, irreversible kinase inhibitors. Science 2005;308:1318-21.
20. Anjum R, Rlenis j. The RSK family of kinases: emerging roles in cellular signalling. Nat Rev Mol Cell Biol 2008;9:747-58.
21. McLeskey SW, Ding Pi', Lippman ME, Kern FG. MDA- MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. Cancer Res 1994;54:523-30.
22. Derksen PW, Liu X, Saridin F, et al. Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 2006;10:437-49.
23. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl j Med 2005;353:172-87.
24. Steeghs N, Nortier JW, Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann Surg Oncol 2007;14:942-53.
25. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl j Med 2008;358:1160-74.
26. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153-8.
27. Knowles MA. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors. Future Oncol 2008;4:71-83.
28. Kwabi-Addo B, Ozen M, Ittmann M. The role of fibroblast growth factors and their receptors in prostate cancer. Endocr Relat Cancer 2004;11:709-24.
29. Grose R, Dickson C. Fibroblast growth factor signaling in turn oogenesis. Cytokine Growth Factor Rev 2005;16:179-86.
30. Bild AFL Yao G( Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7.
31. Sapkota GP, Cummings L, Newell FS, et al. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J 2007; 401:29-38.
32. Cohen MS, Hadjivassiliou FL Taunton J. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK. Nat Chem Biol 2007;3:156-60.
33. Koziczak M, Hynes NE. Cooperation between fibroblast growth factor receptor-4 and ErbB2 in regulation of cyclin DI translation. J Biol Chem 2004;279: 50004-11.
34. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A 1993;90:5889-92.